Cybin (HELP) Total Non-Current Liabilities (2021 - 2024)
Cybin (HELP) reported Total Non-Current Liabilities of -$10.2 million for Q4 2024, down 33253.61% on a YoY basis from N/an in Q1 2024, and up 31.0% quarter-over-quarter from -$14.8 million in Q3 2024.
Cybin (HELP) Total Non-Current Liabilities (2021 - 2024) Analysis & Trends
Cybin has reported Total Non-Current Liabilities for 4 years, with the latest figure at -$10.2 million in Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities fell 33253.61% year-over-year to -$10.2 million; the trailing twelve-month figure through Dec 2024 stood at -$10.2 million (down 33253.61% YoY), and the FY2024 full-year result was -$11.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2024 stood at -$10.2 million, up from -$14.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $864368.4 in Q1 2021, with the low at -$15.2 million in Q2 2024.
- Historically, Total Non-Current Liabilities has averaged -$5.2 million across 4 years, with a median of -$4.4 million in 2021.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 100.64% — and 2024, when it tumbled 33253.61%.
- Cybin's Total Non-Current Liabilities stood at -$4.4 million in 2021, then dropped by 9.02% to -$4.8 million in 2022, then jumped by 100.64% to $30850.5 in 2023, then plunged by 33253.61% to -$10.2 million in 2024.
- The last three Total Non-Current Liabilities figures came in at -$10.2 million (Q4 2024), -$14.8 million (Q3 2024), and -$15.2 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -10.23 Mn |
| Sep 30, 2024 | -14.82 Mn |
| Jun 30, 2024 | -15.23 Mn |
| Mar 31, 2024 | -11.53 Mn |
| Dec 31, 2023 | 30,850.49 |
| Sep 30, 2023 | -3.78 Mn |
| Jun 30, 2023 | 173,457.42 |
| Feb 28, 2023 | 226,867.54 |
| Dec 31, 2022 | -4.79 Mn |
| Sep 30, 2022 | -4.90 Mn |
| Dec 31, 2021 | -4.40 Mn |
| Sep 30, 2021 | -4.47 Mn |
| Jun 30, 2021 | 626,415.91 |
| Mar 31, 2021 | 864,368.44 |